The 2014 Endocrine Society Clinical Practice Guideline on acromegaly suggest measuring IGF-1 levels at 12 weeks or later after pituitary surgery for acromegaly and, as IGF-1 level reflect clinical activity of acromegaly, this measure is used to guide the need for additional treatments, including reoperation, medical treatment, or radiation therapy, and control of GH and IGF-1 excess can reduce morbidity and mortality [9]. This evidence concerns the gene IGF1 and acromegaly.